The research question
What explains treatment interruptions, and how do daily experience and function change over time?
Proposed design
Prospective observational follow-up of adults starting or continuing prescribed weight-management treatment, with a brief weekly diary.
Illustrative design: 12-week diary with an optional longer follow-up; setup and recruitment are scoped separately.
Data to collect
- Reported product, dose and dose dates
- Nausea, bowel symptoms and appetite
- Refill, cost and access barriers
- Weight source, daily function and reasons for interruption
Planned outputs
- Reported persistence and interruption patterns
- Reasons for stopping or switching
- Symptom and function trajectories with missingness documented
What we confirm with you
We agree the population, sample size, country, collection tools, analysis plan and budget. Collection starts after the required consent, ethics or other permissions and a signed scope are in place.
- Confirm medication and indication definitions
- Distinguish reported doses from dispensing records
- Agree safety reporting and avoid causal drug comparisons without an appropriate design
Clinical records, laboratory results, photographs and device integrations are included only when access, collection quality and permitted use have been verified. Self-reported findings are identified as such.
Research context
These published sources explain the research need or method. They are not RIDLY customers, endorsements or purchase commitments.
- Novo Nordisk position on real-world evidence
Novo Nordisk identifies cardiometabolic evidence needs beyond BMI and describes patient-reported and digital data collection.
- Prime Therapeutics GLP-1 persistence research
The pharmacy-benefit manager studies treatment persistence in claims data. Patient diaries can separately examine reported reasons for interruptions.
Related dataset profiles
For an existing-data inquiry, start with a coverage review.